en ORG-24598

ORG-24598
Names
	IUPAC name 2-[Methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid
Identifiers
CAS Number	372198-97-5 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL360052;
ChemSpider	4470795;
IUPHAR/BPS	4600;
PubChem CID	5311285;
	InChI InChI=1S/C19H20F3NO3/c1-23(13-18(24)25)12-11-17(14-5-3-2-4-6-14)26-16-9-7-15(8-10-16)19(20,21)22/h2-10,17H,11-13H2,1H3,(H,24,25)/t17-/m1/s1 Key: KZWQAWBTWNPFPW-QGZVFWFLSA-N;
	SMILES CN(CCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F)CC(=O)O;
Properties
Chemical formula	C19H20F3NO3
Molar mass	367.368 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ORG-24598 is a selective inhibitor of the type 1 glycine transporter.^[1]

Potential uses

Alcohol use disorder

A test in rats has showed that combining varenicline, bupropion, and an indirect glycine agonist (such as ORG-24598) could be beneficial for treatment of alcohol use disorder.^[2]

Schizophrenia

Studies have shown that glycine re-uptake inhibitors selective for the type 1 transporter may be useful for the treatment of certain schizophrenia symptoms.^[3]^[4]

References

^ "2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-17.
^ Olsson, Yasmin; Lidö, Helga; Ademar, Karin; Cadeddu, Davide; Ericson, Mia; Söderpalm, Bo (January 2024). "The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats". Journal of Neural Transmission (Vienna, Austria: 1996). 131 (1): 95–106. doi:10.1007/s00702-023-02701-x. ISSN 1435-1463. PMC 10769923. PMID 37773223.
^ Chue, Pierre (2013). "Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)". Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN 1873-4286. PMID 23194655.
^ Javitt, Daniel C. (July 2002). "Glycine modulators in schizophrenia". Current Opinion in Investigational Drugs (London, England: 2000). 3 (7): 1067–1072. ISSN 1472-4472. PMID 12186269.

[1] "2-[methyl-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-17.

[2] Olsson, Yasmin; Lidö, Helga; Ademar, Karin; Cadeddu, Davide; Ericson, Mia; Söderpalm, Bo (January 2024). "The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats". Journal of Neural Transmission (Vienna, Austria: 1996). 131 (1): 95–106. doi:10.1007/s00702-023-02701-x. ISSN 1435-1463. PMC 10769923. PMID 37773223.

[3] Chue, Pierre (2013). "Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)". Current Pharmaceutical Design. 19 (7): 1311–1320. doi:10.2174/138161213804805766. ISSN 1873-4286. PMID 23194655.

[4] Javitt, Daniel C. (July 2002). "Glycine modulators in schizophrenia". Current Opinion in Investigational Drugs (London, England: 2000). 3 (7): 1067–1072. ISSN 1472-4472. PMID 12186269.

[1]

[2]

[3]

[4]